For many high‑value therapies, particularly in obesity, cardiometabolic disease, oncology, and rare disease, launches increasingly resemble service businesses that happen to be anchored on a product. Payers and health systems expect manufacturers to contribute to adherence, appropriate use, and care coordination, not only to promotion and access.^[2][5][1]

In response, commercial and patient support business units are building ecosystems that combine:

AI now sits inside many of these components, predicting where patients may face access barriers, discontinue early, or struggle with complex regimens. However, without a clear view of how humans and AI work together, the ecosystem operates below its potential and may introduce new risks.^[3][4][5][1]

What human in the loop really means in this context

In life science business units, human in the loop is not a generic assurance that “someone will review the output.” It is the deliberate design of Human‑AI teams that share responsibility for key decisions in launches, access, and patient support.^[6][3]

Three elements are central:

Human in the loop also implies explicit guardrails: where AI may operate without human review, where human sign‑off is mandatory, and how overrides are managed and monitored over time. In practice, this is less about adding another approval step and more about acknowledging that the unit of design is the team of humans and AI working together, not the algorithm alone.^[4][3][6]

Why commercial and patient support leaders should care

For leaders of commercial, market access, and patient services in big pharma, biotech, and medtech, human in the loop increasingly sits at the intersection of growth, risk, and credibility.^[3][1]

In short, human in the loop is how AI moves from a technical experiment to a repeatable, regulator‑ready way of working that directly affects the P&L.^[1][3]

Where AI‑enabled launch programs typically stall

When AI features in launch and patient support discussions, three stall points often appear:

These stall points are not inherent limitations of AI. They are symptoms of incomplete human in the loop design.

Three scenarios that expose the gap

The following scenarios illustrate where human in the loop design is often missing, and where it can create leverage.

Scenario 1: Prior authorization friction in a complex launch

A specialty therapy launches with an AI model that predicts which new prescriptions are most likely to encounter prior authorization delays. The model feeds a ranked list to the central hub each morning. Volumes are high and staffing is constrained.^[2][5]

Without clear human in the loop design, specialists work through the list opportunistically, focusing on cases that appear easiest to resolve. Some high‑risk patients are contacted days later, once delays are already entrenched. Field teams continue to escalate individual issues through informal channels.

With explicit human in the loop design, a defined role is accountable for high‑risk cases, escalation rules specify when to involve payer account teams or field reimbursement support, and response times are tracked. Leadership sees not only the volume of alerts, but also the proportion resolved within target windows and the downstream effect on time‑to‑therapy.^[1][4]

Scenario 2: Adherence support in a GLP‑1 or cardiometabolic ecosystem

An AI‑enabled engagement platform monitors refill patterns, self‑reported side effects, and interaction data to score patients on likelihood of early discontinuation. Scores feed into a dashboard accessible to patient support teams.^[2][1]

In the absence of well‑designed human in the loop workflows, staff may view the dashboard as informational. Outreach remains largely inbound. High‑risk patients receive the same cadence of communications as others, and discontinuation rates remain higher than expected, especially for segments with competing priorities or social barriers.^[8][2]

In a more intentional design, high‑risk signals generate prioritized worklists for human coaches. Scripts and guidance are aligned to the drivers behind each risk classification. Measurement shifts from “how many messages were sent” to “how many high‑risk patients received timely human support and remained on therapy over a defined period.”^[1][2]

Scenario 3: Market access friction in complex benefit designs

For therapies with intricate benefit designs, AI models can anticipate which provider accounts and patient segments are most likely to encounter coverage and affordability challenges. Insights are sometimes delivered as generic “heat maps” or high‑level risk scores for territories.^[5][1]

If no one is formally responsible for translating these insights into action, field teams may perceive them as interesting but not actionable. Local knowledge often dominates, particularly where representatives have long‑standing relationships in key accounts.^[6][4]

When human in the loop is treated as a design problem, model outputs become inputs for market access and field planning. High‑risk segments inform staffing levels, training priorities, and proactive collaboration with hubs. Decision makers can compare regions where Human‑AI teams are structured around these insights with those where traditional models persist, and can adjust resourcing accordingly.^[4][1]

In each scenario, the underlying technology is the constant. The difference lies in whether human in the loop is explicit in the operating model or merely assumed.

Implications for commercial and patient support leaders

For heads of commercial, market access, and patient services, the central question is no longer whether AI can produce meaningful scores and journeys. It is whether business units are prepared to redesign service lines so that humans and AI work together in a disciplined way.^[3][6]

Several implications follow.

These are strategic choices rather than technical configuration details.

Questions for leadership teams

For many organizations, a productive next step is a focused leadership discussion on where human in the loop design is explicitly defined and where it is assumed.

Leaders can start with three questions:

Answering these questions clearly can be more powerful than adding another model or channel, and can help business units turn AI‑enabled ecosystems from slideware into tangible commercial and patient impact.^[3][1]

References